SELECT analysis links semaglutide to slower dementia protein signature

The wire

1. 01A post hoc analysis of 2,970 older SELECT participants found semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk over 104 weeks.
2. 02Clinicians fielding questions about cognitive effects of incretins now have a biomarker signal, though it sits alongside ongoing dedicated cognition trials.
3. 03Whether the proteomic changes translate into less cognitive decline or fewer dementia diagnoses remains unknown, and this is a post hoc analysis of a cardiovascular outcomes trial.

From the source

Semaglutide slows blood protein signature linked to future dementia risk

A post hoc analysis of 2,970 older SELECT participants found that semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk. Over 104 weeks, semaglutide produced larger effects on modeled 5-year than 20-year dementia risk, but whether these biomarker changes translate into less cognitive decline or dementia remains unknown.